Pub. Date : 2005 May
PMID : 15689501
7 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | The purpose of this study is to quantify the capability of verapamil, a mechanism-based inhibitor of CYP3A, and its metabolites to inhibit the activities of CYP3A4 and CYP3A5, and to determine whether CYP3A5 expression in human liver microsomes alters the inhibitory potency of verapamil. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 6 | The possibility that verapamil and its metabolites form metabolic-intermediate complex (MIC) with CYP3A was assessed using dual beam spectrophotometry. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 7 | These findings indicate that the presence of variable CYP3A5/CYP3A4 expression in the liver may contribute to the interindividual variability associated with verapamil-mediated drug interactions. | Verapamil | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |